Laxminarayan Bhat, PhD
Dr. Bhat founded Reviva Pharmaceuticals (Reviva) in 2006 and since its inception, Reviva has advanced extremely rapidly under his leadership, with a portfolio of proprietary compounds at different stages in a pipeline encompassing chronic diseases in large therapeutic areas such as CNS, metabolic, cardiovascular and pain. Dr. Bhat has developed and implemented innovative financing and business models with strategies that have greatly accelerated the drug discovery and development process, resulting in significant savings of time and costs but without sacrificing quality.
Dr. Bhat has over 20 years’ experience in drug discovery and development and prior to founding Reviva, he held research positions at XenoPort, ARYx Therapeutics and Higuchi Biosciences Center in the United States. Dr. Bhat has received a global post-doctoral training at the University of Kansas, USA, the Georg-August-Universität, Göttingen, Germany and the Université du Maine, France. In 1995, he was selected for the Alexander von Humboldt fellowship, an internationally recognized award for young scientists to pursue advanced research in Germany. Dr. Bhat received his Ph.D. in synthetic organic chemistry from the Central University (NEHU), India and has authored over 25 research papers published in peer-reviewed scientific journals. Dr. Bhat is an inventor on more than 100 filed patents and over 45 granted patents.
Marc Cantillon, MD
Dr. Cantillon brings over 20 years drug development experience in NIH, academia and pharmaceutical industry with roles of increasing responsibility and scope at AstraZeneca, Sanofi-Aventis, Wyeth/Pfizer, Schering-Plough/Merck Sharp & Dohme Corp, and consultancy for pharmaceutical, biotech and venture investment firms.
He has expertise in translational Proof-of-Mechanism (POM), Proof-of-Concept (POC) and Phases I through IV trials and development in diverse therapeutic areas, but core expertise in the central nervous system as anesthesiology, neurology, and psychiatry. He is a board certified by American Board of Neurology and Psychiatry (ABPN) in psychiatry, and also passed the ABPN specialty exam in Geriatric psychiatry (1994).
Dr. Cantillon has extensive global clinical trial and successful regulatory experience. He has Initiated and built collaborative strategic partnerships as Coalition for Major Diseases CAMD, QIBA DCE-MRI and FDG-PET steering committees of Radiology Society of North America (RSNA), Alzheimer Disease Neuroimaging (ADNI), Parkinson’s Progression Markers Initiative, Michael J. Fox Foundation and International Society to Advance Alzheimer Research and Treatment. Dr. Cantillon is an author/coauthor of over 40 research articles published in the peer reviewed journals and two books.
Narayan is active at UCSF Medical School and the Berkeley Skydeck Fund working with early-stage life sciences, therapeutics and software ventures in partnership with UCSF and Berkeley researchers. Mr. Prabhu is a Veteran and served two tours of duty as a Captain and Company Commander in the U.S. Army. Narayan is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting and Finance from Indiana University at Bloomington – Kelley School of Business and an MBA from the University of California at Berkeley – Haas School of Business.